Penpulimab plus anlotinib as first-line treatment for persistent, recurrent, or metastatic cervical cancer: A multicentre, single-arm, phase II trial.
| Published in: | Journal of Clinical Oncology Vol. 44; pp. 211 - 234 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Published: |
American Society of Clinical Oncology
2026 Supplement 19
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=194781332&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 194781332 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 0732183X 20D jtl: Journal of Clinical Oncology issn: 0732183X maglogo: N pubinfo: dt: 2026 Supplement 19 vid: 44 pid: 26892 pub: American Society of Clinical Oncology place: Alexandria, Virginia artinfo: ui: 194781332 10.1200/JCO.2026.44.19_suppl.211 194781332 ppf: 211 ppct: 23 formats: tig: atl: Penpulimab plus anlotinib as first-line treatment for persistent, recurrent, or metastatic cervical cancer: A multicentre, single-arm, phase II trial. aug: au: Qiu, Haifeng Guo, Ruixia affil: Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|